Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM163700 (N-(5-((4-((4-ethylpiperazin-1-yl)methyl)-3-(triflu...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.43 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM437992 (US10597387, Compound (I-8)) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.33 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM375276 (US10597387, Compound (I-1) | US9908872, Compound (...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM375281 (US10597387, Compound (I-4) | US9908872, Compound (...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 22.8 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM375276 (US10597387, Compound (I-1) | US9908872, Compound (...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 22.9 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM163700 (N-(5-((4-((4-ethylpiperazin-1-yl)methyl)-3-(triflu...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 25.3 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM375307 (US10597387, Compound (I-6) | US9908872, Compound (...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 29.9 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM375308 (US10597387, Compound (I-7) | US9908872, Compound (...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 56.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM375280 (US10597387, Compound (I-3) | US9908872, Compound (...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 62.2 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM437992 (US10597387, Compound (I-8)) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 69.7 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase HCK (Homo sapiens (Human)) | BDBM375299 (US10597387, Compound (I-5) | US9908872, Compound (...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 117 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM375280 (US10597387, Compound (I-3) | US9908872, Compound (...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 196 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM375281 (US10597387, Compound (I-4) | US9908872, Compound (...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 459 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM375307 (US10597387, Compound (I-6) | US9908872, Compound (...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.15E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM375307 (US10597387, Compound (I-6) | US9908872, Compound (...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM375308 (US10597387, Compound (I-7) | US9908872, Compound (...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.42E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM375299 (US10597387, Compound (I-5) | US9908872, Compound (...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.91E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM375276 (US10597387, Compound (I-1) | US9908872, Compound (...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.21E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear receptor subfamily 2 group C member 2 (Homo sapiens (Human)) | BDBM375299 (US10597387, Compound (I-5) | US9908872, Compound (...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Dana-Farber Cancer Institute, Inc. US Patent | Assay Description The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening... | US Patent US10597387 (2020) BindingDB Entry DOI: 10.7270/Q2ZC85X9 | |||||||||||
More data for this Ligand-Target Pair |